Pegfilgrastim and daily granulocyte colony-stimulating factor: Patterns of use and neutropenia-related outcomes in cancer patients in Spain - Results of the LEARN Study

European Journal of Cancer Care

Volumn 18, Issue 3, 2009, Pages 280-286

  Almenar, D ^a   Mayans, J ^b   Juan, O ^b   Bueno, J M Garcia ^c   Lopez, J I Jalon ^d   Frau, A ^e   Guinot, M ^f   Cerezuela, P ^g   Buscalla, E Garcia ^h   Gasquet, J A ^h   Sanchez, J ^h  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^d HOSPITAL RUBER INTERNACIONAL   (Spain)

^e HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^f HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^g Allergy Section   (Spain)

^h Amgen SA   (Spain)

Author keywords

Febrile neutropenia; G CSF; Neutropenia; Pattern of use; Pegfilgrastim

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; FILGRASTIM; PEGFILGRASTIM; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FEVER; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; NEUTROPENIA; RETROSPECTIVE STUDY; SPAIN; CHEMICALLY INDUCED; NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FEVER; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; SPAIN; YOUNG ADULT; RECOMBINANT PROTEINS;

EID: 65349169512     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2008.00959.x     Document Type: Article

References (28)

1. Aapro M.S., Cameron D.A., Pettengell R., Bohlius J., Crawford J., Ellis M., Kearney N., Lyman G.H., Tjan-Heijnen V.C., Walewski J., Weber D.C., Zielinski C. The European Organisation for Research and (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 42, 2433 2453. (Pubitemid 44442936)
2. Bonadonna G., Valagussa P., Moliterni A., Zambetti M. Brambilla C. (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. The New England Journal of Medicine 332, 901 906.
3. Bosi A., Szer J., Kassis J., Sierra J., Desborough C. Buchanan K. (2004) A multicenter, double-blind, randomized, Phase II trial comparing pegfilgrastim with filgrastim as an adjunct to chemotherapy for acute myeloid leukemia (AML). Blood 104 (Suppl. 11 247A.
4. Budman D.R., Berry D.A., Cirrincione C.T., Henderson I.C., Wood W.C., Weiss R.B., Ferree C.R., Muss H.B., Green M.R., Norton L. Frei E., 3rd. 1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. Journal of the National Cancer Institute 90, 1205 1211. (Pubitemid 28407086)
5. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., Kris M., Grous J., Picozzi V., Rausch G., Smith R., Gradishar W., Yahanda A., Vincent M., Stewart M. Glaspy J. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. The New England Journal of Medicine 325, 164 170. (Pubitemid 24055286)
6. Crawford J., Kreisman H., Garewal H., Jones S.E., Shoemaker D., Pupa M.R., Armstrong S., Tomita D. Dziem G. (1997) The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Annals of Oncology 8, 117 1124. (Pubitemid 27521219)
7. Crawford J., Althaus B., Armitage A., Blayney D.W., Cataland S., Dale D.C., Demetri G.D., Foran J., Heaney M.L., Htoy S., Kloth D.D., Lyman G.H., Michaud L., Motl S., Vadhan-Raj S., Wong M.K. National Comprehensive Cancer Network (2005) Myeloid growth factors clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 3, 540 555. (Pubitemid 44265428)
8. Dale D., Crawford J. Lyman G. (2001) Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review. Proceedings of the American Society of Clinical Oncology 20, 410a
9. Abstract M., Koelbl H., Baselga J., Galid A., Guillem V., Gascon P., Siena S., Lalisang R.I., Samonigg H., Clemens M.R., Zani V., Liang B.C., Renwick J., Piccart M.J. International Pegfilgrastim 749 Study Group (2003) A randomized, double-blind, multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppresive chemotherapy. Annals of Oncology 14, 29 35.
10. Holmes F.A., O'Shaughnessy J.A., Vukelja S., Jones S.E., Shogan J., Savin M., Glaspy J., Moore M., Meza L., Wiznitzer I., Neumann T.A., Hill L.R. Liang B.C. (2002a) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. Journal of Clinical Oncology 20, 727 731. (Pubitemid 34111380)
11. Holmes F.A., Jones S.E., O'Shaughnessy J.A., Vukelja S., George T., Savin M., Richards D., Glaspy J., Meza L., Cohen G., Dhami M., Budman D.R., Hackett J., Brassard M., Yang B.B. Liang B.C. (2002b) Comparable efficacy and safety profiles on once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Annals of Oncology 13, 903 909. (Pubitemid 34752686)
12. Johnston E., Crawford J., Blackwell S., Bjurstrom T., Lockbaum P., Roskos L., Yang B.B., Gardner S., Miller-Messana M.A., Shoemaker D., Garst J. Schwab G. (2000) Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. Journal of Clinical Oncology 18, 2522 2528. (Pubitemid 30432517)
13. Kloess M., Zeynalova S., Truemper L., Schmits R., Schmitz N., Glass B., Engert A., Metzner B., Pfreundschuh M.G.M. Loeffler M. (2003) Effects of G-CSF schedule on leukocyte recovery and infection rate in the CHOP-14 regimen for elderly patients with aggressive lymphoma. Proceedings of the American Society of Clinical Oncology 22, 597 Abstract 2402). (Pubitemid 36609129)
14. Koumakis G., Vassilomanolakis M., Barbounis V., Hatzichristou E., Demiri S., Plataniotis G., Pamouktsoglou F. Efremidis A.P. (1999) Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 56, 28 35. (Pubitemid 29043893)
15. Kuderer N.M., Dale D.C., Crawford J. Lyman G.H. (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. Journal of Clinical Oncology 25, 3158 3167. (Pubitemid 47218066)
16. Lyman G.H. (2005) Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. Journal of the National Comprehensive Cancer Network 3, 557 571. (Pubitemid 44265429)
17. Lyman G.H., Kuderer N.M. Djulbegovic B. (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. American Journal of Medicine 112, 406 411. (Pubitemid 34246271)
18. Mayordomo J.I., Lopez Pousa A., Arocho R., Doan Q.V., Dubois R.W., Liu Z. (2006) Primary prophylaxis with pegfilgrastim is cost-saving compared with filgrastim for breast cancer in Spain. Value in Health 9, A277 (Abstract PCN 6).
19. Mucenski J.W. Shogan J.E. (2003) Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor. Journal of Managed Care Pharmacy 9 (Suppl. 2 10 14.
20. Scott S.D., Chrischilles E.A., Link B.K., Delgado D.J., Fridman M. Stolshek B.S. (2003) Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. Journal of Managed Care Pharmacy 9 (Suppl. 2 15 21.
21. Siena S., Piccart M.J., Holmes F.A., Glaspy J., Hackett J. Renwick J.J. (2003) A combined analysis of two pivotal randomised trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncology Reports 10, 715 724.
22. Sierra J., Szer J., Kassis J., Herrmann R., Lazzarino M., Thomas X., Noga S.J., Baker N., Dansey R. Bosi A. (2008) A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients with low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer (in press).
23. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., Bennett C.L., Cantor S.B., Crawford J., Cross S.J., Demetri G., Desch C.E., Pizzo P.A., Schiffer C.A., Schwartzberg L., Somerfield M.R., Somlo G., Wade J.C., Wade J.L., Winn R.J., Wozniak A.J. Wolff A.C. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guideline. Journal of Clinical Oncology 24, 3187 3205. (Pubitemid 46638957)
24. Trillet-Lenoir V., Green J., Manegold C., Von Pawel J., Gatzemeier U., Lebeau B., Depierre A., Johnson P., Decoster G., Tomita D. Ewen C. (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer 29A, 319 324. (Pubitemid 23025731)
25. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., Tjulandin S.A., Barajas-Figueroa L.J., Wiens B.L., Neumann T.A. Schwartzberg L.S. (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 23, 1178 1184. (Pubitemid 46202274)
26. Von Minckwitz G., Kummel S., du Bois A., Eiermann W., Eidtmann H., Gerber B., Hilfrich J., Huober J., Costa S.D., Jackisch C., Grasshoff S.-T., Vescia S., Skacel T., Loibl S., Mehta K.M. Kaufmann M. (2008) Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Annals of Oncology 19, 292 298.
27. Vose J.M., Crump M., Lazarus H., Emmanouilides C., Schenkein D., Moore J., Frankel S., Flinn I., Lovelace W., Hackett J. Liang B.C. (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. Journal of Clinical Oncology 21, 514 519. (Pubitemid 46606482)
28. Yoshida M. Ohno R. (2004) Antimicrobial prophylaxis in febrile neutropenia. Clinical Infectious Diseases 39 (Suppl. 1 S65 S67. (Pubitemid 38971480)